Effect of Pentoxifylline on Proteinuria in Korean Type 2 Diabetic Patients

Effect of Pentoxifylline on Proteinuria in Korean Type 2 Diabetic Patients : Prospective, Randomized, Double Blinded Active Control, Multicenter Study

This multi-center, randomized controlled study aims to evaluate the effects of pentoxifylline on proteinuria in Korean type 2 diabetic patients.

The investigators will recruit adults patients with type 2 diabetes aged over 20 years with spot urine albumin to creatinine ratio over 30mg/g in two consecutive measurements.

Enrolled patients will be randomly assigned to receive pentoxifylline (400mg three times daily) or placebo for 24 weeks.

Fasting blood and spot urine will be collected at baseline, 12 weeks and 24 weeks.

The investigators will evaluate the impact of pentoxifylline on proteinuria in type 2 diabetic patients.

Inclusion Criteria:

• type 2 diabetes mellitus
• age >=20 years
• spot urine albumin/creatinine ratio > 30mg/g in two consecutive measurements
• patients on ACE-inhibitor or ARB as an anti-hypertensive drug
• blood pressure <= 150/100 mmHg
• HbA1c <10%

Exclusion Criteria:

• taking insulin pentoxifylline, cilostazol, ketas, viagra in 3 months
• ischemic heart disease, stroke, malignant disease, severe infection in 6 months
• serum creatinine > 2.0mg/dl
• severe liver disease or AST, ALT > 3* ULM
• taking systemic steroid in 1 month
• pregnant or plan to become pregnant during the clinical trial
• lactation